Bibliographic citations
Palomino, J., (2023). Asociación entre la administración de clozapina y dislipidemia en pacientes con esquizofrenia del centro de Salud Mental Comunitario Quillabamba mayo 2023 [Universidad Andina del Cusco]. https://hdl.handle.net/20.500.12557/5997
Palomino, J., Asociación entre la administración de clozapina y dislipidemia en pacientes con esquizofrenia del centro de Salud Mental Comunitario Quillabamba mayo 2023 []. PE: Universidad Andina del Cusco; 2023. https://hdl.handle.net/20.500.12557/5997
@misc{renati/23867,
title = "Asociación entre la administración de clozapina y dislipidemia en pacientes con esquizofrenia del centro de Salud Mental Comunitario Quillabamba mayo 2023",
author = "Palomino Castro, Jorge Arnaldo",
publisher = "Universidad Andina del Cusco",
year = "2023"
}
Introduction: Schizophrenia is a chronic and severe mental disorder. Clozapine is an atypical antipsychotic used for its treatment. However, this medication may be associated with significant metabolic side effects, such as dyslipidemia. Objective: To evaluate the relationship between the use of clozapine for over 6 months and the presence of dyslipidemia in patients diagnosed with schizophrenia from the Quillabamba Community Mental Health Center in May 2023. Method: A cross-sectional cohort study was conducted, observational, analytical, retrospective, and quantitative in nature, involving 48 patients with schizophrenia. Of these, 24 had been treated with clozapine, and 24 had not. Various parameters were compared, including age, body mass index (BMI), duration of treatment, duration of illness, gender, presence of comorbidities, and prior medication. In addition, serum lipid levels (total cholesterol, HDL, LDL, and triglycerides) were measured in both groups. Results: The findings indicate significant differences in the lipid profile between patients treated with clozapine for more than 6 months and those who were not. The average levels of total cholesterol (222.88 mg/dL vs 198.33 mg/dL, p=0.034), LDL (139.63 mg/dL vs 126.63 mg/dL, p=0.042), and triglycerides (174.38 mg/dL vs 148.71 mg/dL, p=0.036) were significantly higher in patients treated with clozapine, while average HDL levels did not show a significant difference (42.92 mg/dL vs 44.67 mg/dL, p=0.063). Conclusion: The results suggest a significant association between clozapine administration and dyslipidemia in patients with schizophrenia. This emphasizes the importance of regularly monitoring lipids in these patients to identify and promptly address any metabolic alterations.
This item is licensed under a Creative Commons License